Eledon Pharmaceuticals, Inc. ELDN R2K
Healthcare · Biotechnology · United States
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
READ MORE ›$3.81
+27.00% 1Y
Market & Price
Market Cap
$294.09M
Current Price
$3.81
High / Low (52W)
$4.36 / $1.39
Beta
0.95
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.32
Price to Book
2.88
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-55.26%
ROE
-72.68%
ROA
-35.09%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.33
EPS (TTM)
$-0.77
Balance Sheet & Liquidity
Debt/Equity
0.55
Quick Ratio
8.30
Current Ratio
8.44
Debt
$555.00K
Total Assets
$169.01M
Current Assets
$135.69M
Working Capital
$117.34M
Ownership
Promoter Holding
1.09%
Chg in Prom Hold
-
FII / Inst Holding
59.24%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$183.55M
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-39.67M
Operating Cash Flow
$-68.89M
Shares Outstanding
77.19M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
16.05%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Profit CAGR of 16.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELDN Eledon Pharmaceuticals, Inc. R2K | 3.81 | - | $294.09M | - | -55.26% | -72.68% | - | 16.05% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.96M | 24.73M | 19.07M | 21.48M | 21.18M |
| Operating Income | -6.42M | -6.26M | -13.30M | -8.98M | -11.91M | -11.07M | -11.48M | -932.00K | -1.62M | -3.76M | -1.39M | -6.67M | -2.96M | -2.79M | -3.19M | -3.50M | -4.88M | -4.09M | -2.92M | -3.38M | -2.59M | -6.15M | -9.01M | -7.97M | -10.51M | -9.86M | -9.28M | -10.60M | -11.11M | -10.35M | -11.20M | -10.87M | -14.50M | - | - | -17.96M | -24.73M | -19.07M | -21.48M | -21.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.96M | -24.73M | -19.07M | -21.40M | -21.18M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.50M | -11.22M | -17.46M | -10.41M | -39.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.39M | -6.21M | -13.26M | -8.96M | -11.85M | -11.02M | -11.43M | -1.00M | -2.04M | -3.74M | -1.37M | -6.66M | -2.97M | -2.81M | -3.19M | -3.50M | -4.88M | -4.09M | -2.89M | -8.18M | -2.59M | -6.14M | -8.50M | -7.38M | -9.82M | -9.86M | -9.25M | -10.47M | -10.77M | -65.76M | -9.91M | -23.63M | -44.91M | - | - | -6.50M | -11.22M | -17.46M | -10.45M | -39.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.50 | -0.66 | -0.69 | -0.65 | -0.73 | -0.75 | -2.74 | -0.33 | -0.79 | -0.92 | -0.32 | - | -0.08 | -0.13 | -0.21 | - | -0.33 |
| R&D Expense | 2.83M | - | 10.56M | 5.86M | 8.49M | - | 7.93M | 592.00K | 1.05M | - | 479.00K | 533.00K | 517.00K | 1.10M | 1.33M | 1.65M | 2.99M | 2.30M | 1.51M | 1.65M | 832.00K | 615.00K | 5.65M | 4.24M | 7.66M | 6.63M | 5.74M | 7.45M | 8.11M | 7.20M | 7.93M | 7.41M | 10.11M | 16.52M | - | 13.53M | 20.28M | 14.97M | - | 17.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 39.78M | 43.00M | 70.58M | 83.25M |
| Operating Income | -9.65M | -15.75M | -23.46M | -45.26M | -5.13M | -13.12M | -14.06M | -16.05M | -18.46M | - | -39.78M | -43.00M | -70.58M | -83.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -39.41M | -42.63M | -70.22M | -82.94M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -87.97M | -116.54M | -35.75M | -45.58M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 431.00K | 35.00K |
| Net Income | -9.65M | -15.72M | -23.30M | -45.09M | -5.66M | -13.12M | -14.06M | -16.01M | -22.81M | - | -87.97M | -116.54M | -36.18M | -45.62M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -6.16 | -3.74 | -0.66 | -0.52 |
| R&D Expense | 7.37M | 12.20M | 14.58M | 32.64M | 3.19M | 2.02M | 6.82M | 8.13M | 6.13M | 23.73M | 27.08M | 30.31M | 51.96M | 66.27M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 16.05% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +27.00% |
| 6 Months: | +128.14% |
| 3 Months: | +45.42% |
| 1 Month: | +14.07% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 32.29M | 107.74M | 67.97M | 1.20M | 20.89M | 17.03M | 10.93M | 197.19M | - | 92.79M | 89.07M | 177.41M | 169.01M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 59.52M | 56.13M | 143.73M | 135.69M |
| Cash & Equivalents | 2.25M | 11.69M | 31.75M | 105.26M | 24.02M | 1.10M | 17.23M | 12.97M | 8.79M | 114.19M | - | 56.41M | 4.61M | 20.55M | 22.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 625.00K | 514.00K |
| Total Liabilities | - | - | 2.21M | 4.24M | 6.25M | 3.90M | 1.44M | 2.53M | 1.47M | 6.59M | - | 8.61M | 81.86M | 114.96M | 87.92M |
| Current Liabilities | - | - | 2.21M | 4.24M | 6.16M | 2.82M | - | 2.53M | 1.32M | 2.48M | - | 6.47M | 3.90M | 11.58M | 18.34M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 746.00K | 383.00K | 954.00K | 641.00K |
| Total Equity | -30.43M | -39.90M | -55.27M | 103.50M | 2.78M | -2.70M | 19.45M | 14.49M | 9.46M | 190.60M | - | 84.18M | 7.21M | 62.45M | 81.08M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 13.78M | 24.21M | 59.79M | 75.43M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -14.94M | -11.89M | -13.86M | -15.21M | - | -28.42M | -39.53M | -47.27M | -62.34M |
| Investing Cash Flow | - | - | - | - | - | 23.26M | - | - | 11.04M | - | 0 | -45.29M | -70.31M | 10.79M |
| Financing Cash Flow | - | - | - | - | - | 7.87M | 7.56M | 9.68M | 109.58M | - | 0 | 33.02M | 133.52M | 53.81M |
| Capital Expenditure | -8.00K | -23.00K | -25.00K | -565.00K | -9.00K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -28.42M | -39.53M | -47.27M | -62.34M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -28.42M | -51.80M | 15.94M | 2.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 24.2% | 28.5% | -22.5% | -1,620.7% | 209.3% | -67.4% | -97.1% | -169.2% | -12.0% | - | -104.5% | -1,616.8% | -57.9% | -56.3% |
| ROCE % | - | -52.4% | -22.7% | -73.2% | 316.0% | - | -97.0% | -167.0% | -9.5% | - | -46.1% | -50.5% | -42.6% | -55.3% |
Shareholding Pattern
Insiders
1.09%
Institutions
59.24%
Public Float
59.89%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 8.15% | 6.29M | $23.98M |
| 2 | Blackrock Inc. | 5.68% | 4.38M | $16.70M |
| 3 | Defilade Capital Management, L.P. | 4.62% | 3.56M | $13.58M |
| 4 | Vanguard Capital Management LLC | 4.27% | 3.29M | $12.55M |
| 5 | Ensign Peak Advisors, Inc | 3.19% | 2.46M | $9.39M |
| 6 | Zimmer Partners, Lp | 2.43% | 1.88M | $7.14M |
| 7 | Geode Capital Management, LLC | 2.32% | 1.79M | $6.83M |
| 8 | Sphera Funds Management Ltd. | 2.30% | 1.77M | $6.75M |
| 9 | Catalio Capital Management, LP | 2.12% | 1.64M | $6.25M |
| 10 | Blue Owl Capital Holdings LP | 1.84% | 1.42M | $5.41M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELDN
No recent headlines available.